Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia

Carmen Gasca-Salas1,2,3, Daniel García-Lorenzo4, David Garcia-Garcia1,2,5,6

  • 1Neurosciences Area, CIMA, Department of Neurology and Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.

Insights

Parkinson's disease with mild cognitive impairment (PD-MCI) patients who develop dementia show significant cortical thinning in frontal, insula, and temporal areas. This MRI finding may help identify individuals at higher risk for dementia progression.

Area of Science:

  • Neurology
  • Neuroimaging
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) in Parkinson's disease (PD) is a significant risk factor for dementia.
  • Identifying PD-MCI patients at high risk for dementia progression is crucial for timely intervention.

Purpose of the Study:

  • To investigate patterns of regional brain atrophy in PD-MCI patients who converted to dementia within 31 months.
  • To determine if cortical thickness differences at baseline predict dementia conversion in PD-MCI.

Main Methods:

  • Cortical thickness analysis using MRI in 23 PD-MCI patients and 18 controls.
  • Longitudinal follow-up over 31 months to assess dementia conversion.
  • Comparison of baseline MRI and neuropsychological data between PD-MCI converters and non-converters.

Main Results:

  • PD-MCI patients who converted to dementia (PD-MCI converters) exhibited thinner cortex bilaterally in frontal, insula, and left middle temporal areas compared to non-converters.
  • Cortical thinning was more widespread in PD-MCI converters relative to controls.
  • No significant baseline clinical or neuropsychological differences were observed between converters and non-converters.

Conclusions:

  • Short-to-mid-term dementia progression in PD-MCI is associated with specific patterns of cortical thinning.
  • MRI-based cortical thickness analysis can serve as a valuable tool for identifying PD-MCI patients at elevated risk of dementia.
  • Early identification of at-risk individuals can facilitate targeted therapeutic strategies.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
608
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K